StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Eli Lilly & Co. (LLY) Announces Solanezumab Phase 3 in Alzheimer's Disease Missed Primary Endpoint
November 23, 2016 6:45 AM
Eli Lilly and Company (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Management Comments
Trader Talk
Next Articles
Eli Lilly (LLY) PT Cut to $92 at Leerink Partners
November 23, 2016 2:57 PM
BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's Failure
November 23, 2016 1:48 PM
Eli Lilly & Co. (LLY) AD Portfolio Uncertain Following Sola Failure - Leerink
November 23, 2016 7:48 AM
Eli Lilly & Co. (LLY) CEO Lechleite Not Concerned About Dividend - CNBC
November 23, 2016 7:22 AM
Eli Lilly & Co. (LLY) Sinks 11% on Solanezumab Failure
November 23, 2016 6:54 AM
Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial
November 23, 2016 6:45 AM
Stocks with Implied Volatility Movement
November 23, 2016 5:02 AM
Survey Reveals Most People Don't Know Heart Disease Is the No. 1 Killer of People with Type 2 Diabetes
November 22, 2016 9:00 AM
QuintilesIMS (Q) Enters anti-Cancer Treatment Collaborations with Leading Pharma Companies (PFE) (BMY)
November 22, 2016 8:04 AM
Stocks with call price movement; TSLA LLY
November 21, 2016 11:51 AM
Stocks with Implied Volatility Movement
November 21, 2016 5:26 AM
